OTOİMMUN OLAYLARIN BİRLİKTELİĞİNE BİR ÖRNEK: CROHN HASTALIĞI VE FULMİNAN ROZASEA

2012
Volume: 
75
Number: 
1
Sayfa Aralığı:: 
10-11
Publication Language: 
Turkish
Abstract (Original Language): 
Crohn hastalarının 25%’inde bağırsak dışı tutulum görülebilir. Literatürde Crohn hastalığı ile ilişkili rozacea fulminans ve bunun tedavisine ilişkin data yetersizdir. Rosacea fulminans lokal ve sistemik tedavilere dirençli otoimmun nedenlere bağlı olduğu düşünülen yüz dermatozudur. Bu çalışmada lokal tedavilere yanıtsız olup, sistemik steroid tedavisi sonrasında fulminan rozacea lezyonlarında gerileme olduğunu gözlemlediğimiz kolonik tutulumlu bir Crohn hastasını klinisyenlerin dikkatine sunmak istedik.
Abstract (2. Language): 
Inflammatory bowel disease is one the important diseases of intestinal system with high morbidity and mortality rates. Crohn’s disease also known as a regional enteritis can exhibit of extraintestinal system in one four of these patients. Fulminant rosacea is an autoimmune otoimmun disorder of the cutaneous system. Data regarding fulminant rosacea with Crohn’s disease and treatment approach were insufficient. We report a case presented with otoimmun cutaneous involvement and Crohn’s disease.
Keywords (Original Language): 
References: 

1. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease: A prospective study of 792 patients. J Clin Gastroenterol 23:29, 1996.
2. Baumgart DC, Sandborn WJ. "Inflammatory bowel disease: clinical aspects and established and evolving therapies”. The Lancet 369 (9573): 1641–1657, 2007.
3. Danzi JT: Extraintestinal manifestations of idiopathic inflammatory bowel disease. Arch Intern Med 148:297, 1988.
4. Farmer RG, Hawk WA, Turnbull Jr RB: Clinical patterns in Crohn's disease: A statistical study of 615 cases. Gastroenterology 68: 627, 1975.
5. Gatzka M, simon M. Rosacea fulminans, pyostomatitis and pyovulvitis in Crohn disease: dapson as key factor in combination therapy. Hautazt 57:898-902, 2006.
6. Millikan L. Recognizing rosacea. Postgrad Med 105: 153-158, 1999.
7. Blount BW, Pelletier AL. Rosacea: A common, yet commonly overlooked, condition. Am Fam Physician 66: 435-440, 2002.
8. Rebora A. Rosacea. J Invest Dermatol. 88: 56-60, 1987.
9. Nunzi E, Rebora A, Hamerlinck F. Immunopathological studies on rosacea. Br J Dermatol 103:543, 1980.
10. Bormann G, Gaber G, Fischer M, Marsch WC. Dapsone in rosacea fulminans. J Eur Acad Dermatol Venereol. 15:465-467, 2001.

Thank you for copying data from http://www.arastirmax.com